Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Prenetics Global Ltd(PRE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PRE
11/13/2026: PRE (1-star) is currently NOT-A-BUY. Pass it for now.
Prenetics Global Ltd is a health-tech company that specializes in genetic testing and diagnostic services, operating primarily through its CircleDNA and clinical oncology platforms. The company successfully scaled during the pandemic and has since restructured to focus on its core genomic and clinical services. Its main strength lies in its established regional presence and ability to integrate diagnostic technology into consumer-friendly digital experiences. However, investors must consider the risks of high competition from large diagnostic firms, reliance on discretionary wellness spending, and the company's ongoing transition to sustainable profitability. It is a stock better suited for investors with a higher risk tolerance focused on the long-term potential of precision medicine.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to the health-tech sector but requires proof of sustained, profitable growth. |
| Momentum investor | Weak fit | The stock lacks consistent upward price momentum and is currently out of favor with major institutional momentum strategies. |
| Value investor | Weak fit | The lack of consistent earnings makes it difficult to justify a traditional value-based investment thesis. |
| Dividend investor | Weak fit | The company does not provide income through dividends. |
| Low-risk investor | Weak fit | High volatility and the risks inherent in the growth-stage health-tech sector make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap stocks in the health-tech sector often experience significant price swings. |
| Valuation risk | Medium / high | Determining fair value is difficult due to the transition from COVID-related revenues to core diagnostic growth. |
| Competition risk (Genomic testing) | High | Competition from well-capitalized firms like 23andMe and clinical giants creates a difficult moat. |
| Business quality | Medium | While the technology is innovative, the company is still establishing a consistent, sustainable business model. |
| Dividend income | Low / none | Investors should not expect any income from this holding. |
| Execution risk | High | Successfully integrating and scaling new acquisitions like ACT Genomics is critical for long-term viability. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 322.18M USD | Price to earnings Ratio - | 1Y Target Price 38.44 |
Price to earnings Ratio - | 1Y Target Price 38.44 | ||
Volume (30-day avg) 191.9K shares | Beta 0.4 | 52 Weeks Range 11.37 - 27.24 | Updated Date 11/14/2026 |
52 Weeks Range 11.37 - 27.24 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.1 |
Sector & Industry Intelligence
Sector
Consumer Defensive
Defensive- Sentiment
- Correction Expected
- Momentum
- BUY Breadth Improving
- BUY participation
- 95.0%
- Active BUY / eligible
- 19 / 20
- 30-Day BUY Count Change
- +13
- Market state
- Correction Expected
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Industry classification is unavailable for this snapshot.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -21.76% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CircleDNA | Direct-to-consumer genetic testing kits and subscription health insights. | Revenue comes from people buying tests to learn about their health. |
| Clinical Diagnostics | Genomic profiling and oncology testing for medical providers. | Revenue comes from laboratory services used by doctors to treat patients. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 215.03M | Price to Sales(TTM) 2.08 |
Enterprise Value 215.03M | Price to Sales(TTM) 2.08 | ||
Enterprise Value to Revenue 1.41 | Enterprise Value to EBITDA 0.14 | Shares Outstanding 17.93M | Shares Floating 12.78M |
Shares Outstanding 17.93M | Shares Floating 12.78M | ||
Percent Insiders 18.26 | Percent Institutions 10.92 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.